DE60236939D1 - Hemmung der neurodegeneration - Google Patents

Hemmung der neurodegeneration

Info

Publication number
DE60236939D1
DE60236939D1 DE60236939T DE60236939T DE60236939D1 DE 60236939 D1 DE60236939 D1 DE 60236939D1 DE 60236939 T DE60236939 T DE 60236939T DE 60236939 T DE60236939 T DE 60236939T DE 60236939 D1 DE60236939 D1 DE 60236939D1
Authority
DE
Germany
Prior art keywords
neurodegeneration
inhibition
disease
alzheimer
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60236939T
Other languages
English (en)
Inventor
Jack R Wands
La Monte Suzanne M De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhode Island Hospital
Original Assignee
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital
Application granted granted Critical
Publication of DE60236939D1 publication Critical patent/DE60236939D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE60236939T 2001-06-01 2002-05-28 Hemmung der neurodegeneration Expired - Lifetime DE60236939D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/872,968 US6770797B2 (en) 2001-06-01 2001-06-01 Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid
PCT/US2002/016429 WO2002099036A2 (en) 2001-06-01 2002-05-28 Inhibition of neurodegeneration

Publications (1)

Publication Number Publication Date
DE60236939D1 true DE60236939D1 (de) 2010-08-19

Family

ID=25360708

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60236939T Expired - Lifetime DE60236939D1 (de) 2001-06-01 2002-05-28 Hemmung der neurodegeneration

Country Status (8)

Country Link
US (2) US6770797B2 (de)
EP (1) EP1414478B1 (de)
JP (1) JP2005516886A (de)
AT (1) ATE473009T1 (de)
AU (1) AU2002312033B2 (de)
CA (1) CA2448863C (de)
DE (1) DE60236939D1 (de)
WO (1) WO2002099036A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60223524D1 (de) * 2001-05-04 2007-12-27 Nymox Corp Verfahren zur vorbeugung von zelltod unter verwendung von antikörpern gegen neural thread proteine
JP2005535580A (ja) * 2002-04-26 2005-11-24 イアン， エイ． ファーガソン， 血液脳関門を通したポリペプチドの非侵襲的な送達およびエンドサイトーシスリガンドの生体内選択
AU2003233120B2 (en) * 2002-04-26 2008-08-21 Ferguson, Ian Andrew Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands
US7544771B2 (en) * 2005-02-23 2009-06-09 Nymox Corporation Protein and its use in diagnosing Alzheimer's disease
EP2381774A4 (de) * 2008-12-23 2012-07-18 Salk Inst For Biological Studi Verfahren zur behandlung von neurodegenerativen erkrankungen
EP2521914A4 (de) * 2010-01-08 2013-07-10 Oncohealth Corp Zellbasierte hpv-immuntests mit hoher durchlaufleistung zur diagnose und abtastung von hpv-assoziierten krebsen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
CA2109955A1 (en) 1991-05-24 1992-11-26 Toru Hayakawa Equipment for intracerebral administration of preparations
WO1994023756A1 (en) 1993-04-20 1994-10-27 The General Hospital Corporation Neural thread protein gene expression and detection of alzheimer's disease
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5863898A (en) 1996-10-29 1999-01-26 Incyte Pharmaceuticals, Inc. Human lim proteins
JP3758792B2 (ja) 1997-02-25 2006-03-22 三菱重工業株式会社 ガスタービン動翼のプラットフォーム冷却機構
KR20000075748A (ko) 1997-02-26 2000-12-26 마빈 씨. 구트리 알츠하이머 병의 치료 또는 예방에 유효한 약물을 선별하기 위한 유전자 변형동물 및 세포계
CA2323889A1 (en) 1997-03-12 1998-09-17 Robert W. Esmond A method for treating or preventing alzheimer's disease

Also Published As

Publication number Publication date
US20030050262A1 (en) 2003-03-13
AU2002312033B2 (en) 2007-10-18
WO2002099036A3 (en) 2004-01-08
EP1414478A4 (de) 2007-03-21
ATE473009T1 (de) 2010-07-15
US7319094B2 (en) 2008-01-15
EP1414478B1 (de) 2010-07-07
CA2448863A1 (en) 2002-12-12
WO2002099036A2 (en) 2002-12-12
EP1414478A2 (de) 2004-05-06
CA2448863C (en) 2010-05-04
JP2005516886A (ja) 2005-06-09
US6770797B2 (en) 2004-08-03
US20050090441A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
MXPA04004714A (es) Derivados de aril 1,4-pirazina sustituidos.
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
MX2007016136A (es) Metodo para diagnosticar la enfermedad de alzheimer.
PL1765388T3 (pl) Terapia skojarzona do zapobiegania chorobie Alzheimera lub leczenia tej choroby oraz zestaw do tego celu
AU2002232393A1 (en) Methods for identifying genes associated with diseases or specific phenotypes
ATE291423T1 (de) Nicht-peptidische gnrh agentia, verfahren und zwischenverbindungen zur ihren herstellung
WO2002056892A3 (en) Methods of treating neurological disorders
EA200300027A1 (ru) Способ лечения сердечно-сосудистых заболеваний
WO2005004814A3 (en) Sirt1 and genetic disorders
EP1743036A4 (de) Mit dem alter bei erstauftreten von alzheimer im zusammenhang stehende apoe-genmarker
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
DE60236939D1 (de) Hemmung der neurodegeneration
ATE522230T1 (de) Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit
EP1310166A4 (de) Transgener nicht-menschlicher säuger und methode zu seiner herstellung, model einer tierkrankheit und methode zur auklärung einer genfunktion(26.02.02)
BRPI0512125A (pt) barra de sabão
TW200503717A (en) Substituted 1,4-pyrazine derivatives
DE60323034D1 (de) Form zur Herstellung von Modell und Modell zum Feingiessen
WO2001018549A8 (en) Method for identifying modulators of daf-16
WO2005072241A3 (en) Inhibition of bright function as a treatment for excessive immunoglobulin production
WO2002027034A3 (en) Method of identifying genetic regions associated with disease and predicting responsiveness to therapeutic agents
ITTO20010135A0 (it) Struttura di stampo per la produzione di getti metallici di lega leggera e procedimento di colata che l'utilizza.
MXPA02011516A (es) Modelo de animal transgenico de trastornos neurodegenerativos.
DE60133563D1 (de) Külen
DK1670309T3 (da) Transgenetiske dyr med større lidelser i forbindelse med Alzheimers sygdom
WO2002089567A3 (en) Sca2 knockout animal and methods of use